PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery

Biochimica et Biophysica Acta - Biomembranes

Volumn 1778, Issue 1, 2008, Pages 88-96

  Yang, Yang ^a   Shi, Yun ^a   Guo, Shouli ^b   Zhang, Shuang ^b   Cui, Ningren ^a   Shi, Weiwei ^a   Zhu, Daling ^b   Jiang, Chun ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Antagonist; K+ channel; Kir6.1; Second messenger; Vascular tone; VIP

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; POTASSIUM CHANNEL; PROTEIN SUR2B; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; ELECTRIC CONDUCTIVITY; ELECTRIC POTENTIAL; HUMAN; HUMAN CELL; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; ION CHANNEL GATING; ISOENZYMES; KATP CHANNELS; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION;

MUS;

EID: 38149012227     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2007.08.030     Document Type: Article

References (57)

1. Delgado M., Abad C., Martinez C., Laceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7 (2001) 563
2. Straub S.G., and Sharp G.W.G. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. J. Biol. Chem. 271 (1996) 1660
3. Tsutsumi M., Claus T.H., Liang Y., Li Y.X., Yang L., Zhu J., Dela Cruz F., Peng X.B., Chen H.X., Yung S.L., Hamren S., Livingston J.N., and Pan C.Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal - a potential therapy for type 2 diabetes. Diabetes 51 (2002) 1453
4. Laburthe M., and Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regulatory Pept. 108 (2002) 165
5. Henning R.J., and Sawmiller D.R. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49 (2001) 27
6. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., and Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111 (2003) 1339
7. Hamidi S.A., Szema A.M., Lyubsky S., Dickman K.G., Degene A., Mathew S.M., Waschek J.A., and Said S.I. Clues to VIP function from knockout mice. Ann. N.Y. Acad. Sci. 1070 (2006) 5
8. Said S.I., Hamidi S.A., Dickman K.G., Szema A.M., Lyubsky S., Lin R.Z., Jiang Y.P., Chen J.J., Waschek J.A., and Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115 (2007) 1260
9. Hoshino M., Yanaihara C., Hong Y.M., Kishida S., Katsumaru Y., Vandermeers A., Vandermeers-Piret M.C., Robberecht P., Christophe J., and Yanaihara N. Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom. FEBS Lett. 178 (1984) 233
10. Blank M.A., Brown J.R., Hunter J.C., Bloom S.R., and Tyers M.B. Effects of VIP and related peptides and Gila monster venom on genitourinary smooth muscle. Eur. J. Pharmacol. 132 (1986) 155
11. Pohl M., and Wank S.A. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J. Biol. Chem. 273 (1998) 9778
12. Nilsson H. Interactions between membrane potential and intracellular calcium concentration in vascular smooth muscle. Acta Physiol. Scand. 164 (1998) 559
13. 2+ signaling pathways underlying myogenic reactivity. J. Appl. Physiol. 91 (2001) 973
14. ATP channels in vascular smooth muscle. Clin. Exp. Pharmacol. Physiol. 29 (2002) 312
15. Quayle J.M., Nelson M.T., and Standen N.B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 77 (1997) 1165
16. ATP channels. Annu. Rev. Physiol. 60 (1998) 667
17. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 61 (1999) 337
18. Deeley R.G., Westlake C., and Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86 (2006) 849
19. + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am. J. Physiol., Cell Physiol. 43 (1998) C25-C37
20. + channels in rat vascular smooth muscles. Biochem. Biophys. Res. Commun. 296 (2002) 463
21. ATP-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression. Eur. J. Pharmacol. 523 (2005) 109
22. + channels determine their muscle-type-dependent biophysical and pharmacological properties. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1118
23. Zhang H., and Bolton T.B. Activation by intracellular GDP, metabolic inhibition and pinacidil of a glibenclamide-sensitive K-channel in smooth-muscle cells of rat mesenteric-artery. Br. J. Pharmacol. 114 (1995) 662
24. Zhang H.L., and Bolton T.B. Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Br. J. Pharmacol. 118 (1996) 105
25. ATP channels. J. Clin. Invest. 110 (2002) 203
26. Miki T., Suzuki M., Shibasaki T., Uemura H., Sato T., Yamaguchi K., Koseki H., Iwanaga T., Nakaya H., and Seino S. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat. Med. 8 (2002) 466
27. ATP channel imparts fatal susceptibility to endotoxemia. FASEB J. 20 (2006) 2271
28. Quinn K., Giblin J.P., and Tinker A. Protein kinase C regulates Kir6.1/SUR2B current but not Kir6.2/SUR2B current in stably transfected HEK293 cells. J. Physiol. (Lond.) 536 (2001) 20
29. + channel. Circ. Res. 94 (2004) 1359
30. + channels composed of Kir6.1 and/or Kir6.2 expressed with SUR2B. J. Physiol. (Lond.) 541 (2002) 65
31. Shi W., Cui N., Shi Y., Zhang X., Yang Y., and Jiang C. Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am. J. Physiol., Regul. Integr. Comp. Physiol. 293 (2007) R191-R199
32. ATP channel activation by beta-adrenergic receptors. Am. J. Physiol., Regul. Integr. Comp. Physiol. (2007) 00337
33. ATP channels in vascular smooth muscles. Circ. Res. 92 (2003) 1225
34. Simmons N.L. A cultured human renal epithelioid cell line responsive to vasoactive intestinal peptide. Exp. Physiol. 75 (1990) 309
35. Reubi J.C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues-clinical implications. Ann. N.Y. Acad. Sci. 921 (2000) 1
36. Lin Y.F., Jan Y.N., and Jan L.Y. Regulation of ATP-sensitive potassium channel function by protein kinase A-mediated phosphorylation in transfected HEK293 cells. EMBO J. 19 (2000) 942
37. ATP channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J. 18 (1999) 4722
38. 1 using immunoaffinity chromatography: evidence for precoupling. Biochem. Biophys. Res. Commun. 290 (2002) 1300
39. Sawmiller D.R., Ashtari M., Urueta H., Leschinsky M., and Henning R.J. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart. Neuropeptides 40 (2006) 349
40. Tanaka Y., Horikawa N., Ishiro H., Kataha K., Nakazawa T., Watanabe N., Ishii K., Nakayama K., Yanaihara N., and Shigenobu K. Glibenclamide-sensitive mechanism is involved in helodermin-produced vasodilatation in rat mesenteric artery. Res. Commun. Mol. Pathol. Pharmacol. 98 (1997) 141
41. Hattori Y., Nagashima M., Endo Y., and Kanno M. Glibenclamide does not block arterial relaxation caused by vasoactive intestinal polypeptide. Eur. J. Pharmacol. 213 (1992) 147
42. Kawasaki J., Kobayashi S., Miyagi Y., Nishimura J., Fujishima M., and Kanaide H. The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery. Br. J. Pharmacol. 121 (1997) 977
43. + channel Kir6.1. J. Physiol. (Lond.) 508 (1998) 23
44. + channel. J. Biol. Chem. 277 (2002) 21346
45. Liu Y.C., Patel H.J., Khawaja A.M., Belvisi M.G., and Rogers D.R. Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BKCa channels and inhibition of neurotransmitter release. Br. J. Pharmacol. 126 (1999) 147
46. Sari R., Peitl B., Kovacs P., Lonovics J., Palvolgyi A., Hegyi P., Nagy I., Nemeth J., Szilvassy Z., and Porszasz R. Cyclic GMP-mediated activation of a glibenclamide-sensitive mechanism in the rabbit sphincter of Oddi. Dig. Dis. Sci. 49 (2004) 514
47. Li L., Wu J., and Jiang C. Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of various tissues in rats. J. Membr. Biol. 196 (2003) 61
48. ATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol. 5 (2005) 1
49. + channel. J. Physiol. (Lond.) 499 (1997) 715
50. + channels. Mol. Pharmacol. 65 (2004) 1198
51. + channels in smooth muscle. J. Physiol. (Lond.) 572 (2006) 617
52. + currents in rabbit arterial smooth-muscle via protein-kinase-A. J. Physiol. (Lond.) 475 (1994) 9
53. + channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle. J. Physiol. (Lond.) 507 (1998) 117
54. Kurjak M., Fritsch R., Saur D., Schusdziarra V., and Allescher H.D. Functional coupling between nitric oxide synthesis and VIP release within enteric nerve terminals of the rat: involvement of protein kinase G and phosphodiesterase 5. J. Physiol. (Lond.) 534 (2001) 827
55. Kim B.J., Lee J.H., Jun J.Y., Chang I.Y., So I., and Kim K.W. Vasoactive intestinal polypeptide inhibits pacemaker activity via the nitric oxide-cGMP-protein kinase G pathway in the interstitial cells of Cajal of the murine small intestine. Mol. Cells 21 (2006) 337
56. Pomerleau F., Fournier A., and Cadieux A. Mouse aorta: a preparation highly sensitive to the vasodilatory action of CGRP. J. Cardiovasc. Pharmacol. 30 (1997) 343
57. Pesic S., Grbovic L., Radenkovic M., Stojic D., Nikolic V., and Cvetkovic Z. The relaxant effect of vasoactive intestinal polypeptide in the isolated canine uterine artery: the role of endothelium. J. Vet. Med., Ser. A Physiol. Pathol. Clin. Med. 51 (2004) 394